NO321862B1 - Tabletter med farmasoytisk kontrollert frigjoring, som inneholder en baerer basert pa tverrbundet amylose og hydroksypropylmetylcellulose, og anvendelse derav - Google Patents
Tabletter med farmasoytisk kontrollert frigjoring, som inneholder en baerer basert pa tverrbundet amylose og hydroksypropylmetylcellulose, og anvendelse derav Download PDFInfo
- Publication number
- NO321862B1 NO321862B1 NO19984703A NO984703A NO321862B1 NO 321862 B1 NO321862 B1 NO 321862B1 NO 19984703 A NO19984703 A NO 19984703A NO 984703 A NO984703 A NO 984703A NO 321862 B1 NO321862 B1 NO 321862B1
- Authority
- NO
- Norway
- Prior art keywords
- hpmc
- tablet
- cross
- carrier
- amylose
- Prior art date
Links
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 title claims abstract description 84
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 title claims abstract description 84
- 229920000856 Amylose Polymers 0.000 title claims abstract description 38
- 238000013270 controlled release Methods 0.000 title claims abstract description 14
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 title claims description 83
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 title claims description 82
- 239000004480 active ingredient Substances 0.000 claims abstract description 36
- 239000003431 cross linking reagent Substances 0.000 claims description 16
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 claims description 5
- 239000011248 coating agent Substances 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 239000011159 matrix material Substances 0.000 claims description 4
- 230000000181 anti-adherent effect Effects 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 abstract description 24
- 108090000790 Enzymes Proteins 0.000 abstract description 24
- 229940088598 enzyme Drugs 0.000 abstract description 24
- 239000002671 adjuvant Substances 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 8
- 102000004139 alpha-Amylases Human genes 0.000 abstract description 5
- 108090000637 alpha-Amylases Proteins 0.000 abstract description 5
- 230000000968 intestinal effect Effects 0.000 abstract description 5
- 229940024171 alpha-amylase Drugs 0.000 abstract description 3
- 239000003826 tablet Substances 0.000 description 53
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 28
- 239000007891 compressed tablet Substances 0.000 description 16
- 239000002609 medium Substances 0.000 description 15
- 238000004090 dissolution Methods 0.000 description 10
- 230000002255 enzymatic effect Effects 0.000 description 10
- 239000008363 phosphate buffer Substances 0.000 description 9
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 7
- 229960001138 acetylsalicylic acid Drugs 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 239000003814 drug Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000017 hydrogel Substances 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000012736 aqueous medium Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229960003447 pseudoephedrine hydrochloride Drugs 0.000 description 3
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 description 3
- QWVCIORZLNBIIC-UHFFFAOYSA-N 2,3-dibromopropan-1-ol Chemical compound OCC(Br)CBr QWVCIORZLNBIIC-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 229920003091 Methocel™ Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- -1 hydroxymethylpropyl Chemical group 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000000864 hyperglycemic agent Substances 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229960003908 pseudoephedrine Drugs 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002173818A CA2173818A1 (fr) | 1996-04-10 | 1996-04-10 | Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose |
| PCT/CA1997/000229 WO1997037639A1 (fr) | 1996-04-10 | 1997-04-04 | Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO984703D0 NO984703D0 (no) | 1998-10-08 |
| NO984703L NO984703L (no) | 1998-12-08 |
| NO321862B1 true NO321862B1 (no) | 2006-07-17 |
Family
ID=4157953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19984703A NO321862B1 (no) | 1996-04-10 | 1998-10-08 | Tabletter med farmasoytisk kontrollert frigjoring, som inneholder en baerer basert pa tverrbundet amylose og hydroksypropylmetylcellulose, og anvendelse derav |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US5885615A (da) |
| EP (1) | EP0954290B1 (da) |
| JP (1) | JP4166278B2 (da) |
| KR (1) | KR100439614B1 (da) |
| CN (1) | CN1218396A (da) |
| AT (1) | ATE240719T1 (da) |
| AU (1) | AU711089B2 (da) |
| BR (1) | BR9708772A (da) |
| CA (1) | CA2173818A1 (da) |
| CZ (1) | CZ294342B6 (da) |
| DE (1) | DE69722247T2 (da) |
| DK (1) | DK0954290T3 (da) |
| ES (1) | ES2200166T3 (da) |
| IL (1) | IL126477A (da) |
| MY (1) | MY115535A (da) |
| NO (1) | NO321862B1 (da) |
| NZ (1) | NZ332576A (da) |
| PL (1) | PL187764B1 (da) |
| PT (1) | PT954290E (da) |
| TR (1) | TR199802034T2 (da) |
| WO (1) | WO1997037639A1 (da) |
| ZA (1) | ZA973054B (da) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL109460A (en) | 1993-05-10 | 1998-03-10 | Euro Celtique Sa | Controlled release formulation comprising tramadol |
| US6197339B1 (en) * | 1997-09-30 | 2001-03-06 | Pharmacia & Upjohn Company | Sustained release tablet formulation to treat Parkinson's disease |
| US6284273B1 (en) * | 1998-02-24 | 2001-09-04 | Vincent Lenaerts | Cross-linked high amylose starch resistant to amylase as a matrix for the slow release of biologically active compounds |
| DE69940557D1 (de) | 1998-12-11 | 2009-04-23 | Nostrum Pharmaceuticals Inc | Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung |
| US6555139B2 (en) | 1999-06-28 | 2003-04-29 | Wockhardt Europe Limited | Preparation of micron-size pharmaceutical particles by microfluidization |
| EP1174127A1 (en) * | 2000-07-21 | 2002-01-23 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Composition for targeted release of an actvie substance and process for producing such a composition |
| US6673369B2 (en) * | 2001-08-29 | 2004-01-06 | Ranbaxy Laboratories Limited | Controlled release formulation |
| US20030203055A1 (en) * | 2002-03-15 | 2003-10-30 | Cypress Bioscience, Inc. | Methods of treating visceral pain syndromes |
| BR0315657A (pt) * | 2002-10-25 | 2005-09-13 | Labopharm Inc | Formulação de dosagem sólida, comprimido para liberação controlada, método de fabricar uma medicação de liberação controlada, composição farmacêutica e uso de uma composição |
| MY142195A (en) * | 2002-10-25 | 2010-10-15 | Labopharm Inc | Controlled-release compositions |
| US20060003004A1 (en) * | 2002-10-25 | 2006-01-05 | Collegium Pharmaceutical, Inc. | Pulsatile release compositions of milnacipran |
| TWI319713B (en) * | 2002-10-25 | 2010-01-21 | Sustained-release tramadol formulations with 24-hour efficacy | |
| US20040132826A1 (en) * | 2002-10-25 | 2004-07-08 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
| US8487002B2 (en) * | 2002-10-25 | 2013-07-16 | Paladin Labs Inc. | Controlled-release compositions |
| WO2004047651A2 (en) * | 2002-11-25 | 2004-06-10 | Boston Scientific Limited | Injection device for treating mammalian body |
| WO2004067039A1 (en) * | 2003-01-28 | 2004-08-12 | Collegium Pharmaceutical, Inc. | Multiparticulate compositions of milnacipran for oral administration |
| US20060172006A1 (en) * | 2003-10-10 | 2006-08-03 | Vincent Lenaerts | Sustained-release tramadol formulations with 24-hour clinical efficacy |
| AR051654A1 (es) * | 2004-11-04 | 2007-01-31 | Astrazeneca Ab | Nuevas formulaciones de pellets de liberacion modificada para inhibidores de la bomba de protones |
| CA2491665A1 (fr) * | 2004-12-24 | 2006-06-24 | Louis Cartilier | Formulation de comprime pour liberation soutenue de principe actif |
| BRPI0615860B8 (pt) * | 2005-09-09 | 2021-05-25 | Labopharm Barbados Ltd | composição farmacêutica de liberação prolongada monolítica sólida |
| CA2621597C (en) * | 2005-09-21 | 2014-06-10 | Surmodics, Inc. | In vivo formed matrices including natural biodegradable polysaccharides and ophthalmic uses thereof |
| US8512736B2 (en) * | 2005-09-21 | 2013-08-20 | Surmodics, Inc. | Coatings including natural biodegradable polysaccharides and uses thereof |
| CN101304764B (zh) * | 2005-11-11 | 2012-12-05 | 旭化成化学株式会社 | 控释固体制剂 |
| WO2008073295A2 (en) * | 2006-12-07 | 2008-06-19 | Surmodics, Inc. | Latent stabilization of bioactive agents releasable from implantable medical articles |
| WO2009137689A2 (en) | 2008-05-07 | 2009-11-12 | Surmodics, Inc. | Delivery of nucleic acid complexes from particles |
| WO2010028108A2 (en) * | 2008-09-04 | 2010-03-11 | Bristol-Myers Squibb Company | Stable pharmaceutical composition for optimized delivery of an hiv attachment inhibitor |
| EP2362768B1 (en) * | 2008-10-27 | 2016-04-20 | Alza Corporation | Extended release oral acetaminophen/tramadol dosage form |
| US20100260842A1 (en) * | 2009-04-06 | 2010-10-14 | Rashmi Nair | Pseudoephedrine pharmaceutical formulations |
| US8901092B2 (en) | 2010-12-29 | 2014-12-02 | Surmodics, Inc. | Functionalized polysaccharides for active agent delivery |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3065143A (en) * | 1960-04-19 | 1962-11-20 | Richardson Merrell Inc | Sustained release tablet |
| US4167558A (en) * | 1976-02-13 | 1979-09-11 | Hoffmann-La Roche Inc. | Novel sustained release tablet formulations |
| US4389393A (en) * | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
| US4610870A (en) * | 1984-10-05 | 1986-09-09 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
| US4734285A (en) * | 1985-10-28 | 1988-03-29 | The Dow Chemical Company | Sustained release compositions |
| US4704285A (en) * | 1985-11-18 | 1987-11-03 | The Dow Chemical Company | Sustained release compositions comprising hydroxypropyl cellulose ethers |
| US4775535A (en) * | 1986-04-04 | 1988-10-04 | Hans Lowey | Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics |
| US4855143A (en) * | 1986-04-04 | 1989-08-08 | Hans Lowey | Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics |
| US5603956A (en) * | 1990-11-27 | 1997-02-18 | Labopharm Inc. | Cross-linked enzymatically controlled drug release |
| CA2041774C (en) * | 1990-11-27 | 1994-04-19 | Mircea A. Mateescu | Use of cross-linked amylose as a matrix for the slow release of biologically active compounds |
| NL9201196A (nl) * | 1992-07-03 | 1994-02-01 | Tno | Preparaat voor de gereguleerde afgifte van een werkzame stof en werkwijze ter bereiding van een dergelijk preparaat. |
| WO1994002121A1 (en) * | 1992-07-24 | 1994-02-03 | Labopharm Inc. | Cross-linked polyhydroxylic material for enzymatically controlled drug release |
| US5616343A (en) * | 1993-03-25 | 1997-04-01 | Labopharm, Inc. | Cross-linked amylose as a binder/disintegrant in tablets |
| IT1282650B1 (it) * | 1996-02-19 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici |
-
1996
- 1996-04-10 CA CA002173818A patent/CA2173818A1/fr not_active Abandoned
- 1996-08-19 US US08/699,611 patent/US5885615A/en not_active Expired - Lifetime
-
1997
- 1997-04-04 NZ NZ332576A patent/NZ332576A/xx not_active IP Right Cessation
- 1997-04-04 DK DK97915220T patent/DK0954290T3/da active
- 1997-04-04 AU AU22832/97A patent/AU711089B2/en not_active Ceased
- 1997-04-04 PL PL32928597A patent/PL187764B1/pl unknown
- 1997-04-04 TR TR1998/02034T patent/TR199802034T2/xx unknown
- 1997-04-04 WO PCT/CA1997/000229 patent/WO1997037639A1/fr active IP Right Grant
- 1997-04-04 AT AT97915220T patent/ATE240719T1/de active
- 1997-04-04 IL IL12647797A patent/IL126477A/en not_active IP Right Cessation
- 1997-04-04 ES ES97915220T patent/ES2200166T3/es not_active Expired - Lifetime
- 1997-04-04 CN CN97194638A patent/CN1218396A/zh active Pending
- 1997-04-04 JP JP53470597A patent/JP4166278B2/ja not_active Expired - Fee Related
- 1997-04-04 DE DE69722247T patent/DE69722247T2/de not_active Expired - Lifetime
- 1997-04-04 KR KR10-1998-0708056A patent/KR100439614B1/ko not_active IP Right Cessation
- 1997-04-04 EP EP97915220A patent/EP0954290B1/fr not_active Expired - Lifetime
- 1997-04-04 CZ CZ19983254A patent/CZ294342B6/cs not_active IP Right Cessation
- 1997-04-04 BR BR9708772-6A patent/BR9708772A/pt not_active IP Right Cessation
- 1997-04-04 PT PT97915220T patent/PT954290E/pt unknown
- 1997-04-10 MY MYPI97001576A patent/MY115535A/en unknown
- 1997-04-10 ZA ZA9703054A patent/ZA973054B/xx unknown
-
1998
- 1998-10-08 NO NO19984703A patent/NO321862B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| TR199802034T2 (xx) | 1999-02-22 |
| EP0954290A1 (fr) | 1999-11-10 |
| JP2000507561A (ja) | 2000-06-20 |
| KR20000005337A (ko) | 2000-01-25 |
| ATE240719T1 (de) | 2003-06-15 |
| WO1997037639A1 (fr) | 1997-10-16 |
| EP0954290B1 (fr) | 2003-05-21 |
| NZ332576A (en) | 2000-03-27 |
| PL187764B1 (pl) | 2004-10-29 |
| IL126477A (en) | 2001-10-31 |
| AU2283297A (en) | 1997-10-29 |
| BR9708772A (pt) | 2000-01-04 |
| DK0954290T3 (da) | 2003-09-22 |
| ES2200166T3 (es) | 2004-03-01 |
| CA2173818A1 (fr) | 1997-10-11 |
| CZ294342B6 (cs) | 2004-12-15 |
| MY115535A (en) | 2003-07-31 |
| PT954290E (pt) | 2003-10-31 |
| NO984703D0 (no) | 1998-10-08 |
| PL329285A1 (en) | 1999-03-15 |
| KR100439614B1 (ko) | 2004-10-14 |
| CN1218396A (zh) | 1999-06-02 |
| IL126477A0 (en) | 1999-08-17 |
| AU711089B2 (en) | 1999-10-07 |
| DE69722247D1 (de) | 2003-06-26 |
| DE69722247T2 (de) | 2004-04-01 |
| JP4166278B2 (ja) | 2008-10-15 |
| NO984703L (no) | 1998-12-08 |
| US5885615A (en) | 1999-03-23 |
| ZA973054B (en) | 1998-06-01 |
| CZ325498A3 (cs) | 1999-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO321862B1 (no) | Tabletter med farmasoytisk kontrollert frigjoring, som inneholder en baerer basert pa tverrbundet amylose og hydroksypropylmetylcellulose, og anvendelse derav | |
| AU608208B2 (en) | Therapeutic agents | |
| US4389393A (en) | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose | |
| US20030035836A1 (en) | Oral controlled release pharmaceutical composition for once-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases | |
| CN101242856A (zh) | 持续药物释放的组合物 | |
| JP2009538918A (ja) | フェニレフリンを含有する徐放薬学的投薬形態 | |
| MXPA96005646A (en) | Preparation of nifedipine of release prolong | |
| JPH09143073A (ja) | 持続性ニフエジピン製剤 | |
| Leopold et al. | Eudragit® E as coating material for the pH-controlled drug release in the topical treatment of inflammatory bowel disease (IBD) | |
| JP2009543885A (ja) | イブプロフェンの投与のための方法および医薬 | |
| US8604084B2 (en) | Method | |
| CA2443632A1 (en) | Timed pulse release composition | |
| EP1146864B1 (en) | Ph independent extended release pharmaceutical formulation | |
| MXPA04004544A (es) | Sistema de liberacion prolongada para droga soluble. | |
| JPH10509981A (ja) | 高等植物から得られうる粉末状親水コロイドゴムを用いる持効性薬剤送出 | |
| MXPA97004043A (en) | Assortment of pharmacy of sustained release using a rubber of hydrocoloid in powder obtained from top plants | |
| WO1985004099A1 (en) | Sustained release oral dosage form for naproxyn | |
| MXPA98008340A (en) | Spraying module that has a protective element and a recolec element | |
| KR0184350B1 (ko) | 오메프라졸 구강점막 부착 정제 조성물 | |
| WO2000013675A9 (en) | Methazolamide compositions and method of use | |
| MXPA01007814A (es) | Formulacion farmaceutica de libekracion prolongada independiente al ph |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |